1502 related articles for article (PubMed ID: 15726519)
21. Sparing the parotid glands and surgically transferred submandibular gland with helical tomotherapy in post-operative radiation of head and neck cancer: a planning study.
Saibishkumar EP; Jha N; Scrimger RA; MacKenzie MA; Daly H; Field C; Fallone G; Parliament MB
Radiother Oncol; 2007 Oct; 85(1):98-104. PubMed ID: 17923162
[TBL] [Abstract][Full Text] [Related]
22. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
23. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
[TBL] [Abstract][Full Text] [Related]
24. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
25. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
[TBL] [Abstract][Full Text] [Related]
26. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
27. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
28. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy.
Marzi S; Iaccarino G; Pasciuti K; Soriani A; Benassi M; Arcangeli G; Giovinazzo G; Benassi M; Marucci L
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1252-9. PubMed ID: 19251097
[TBL] [Abstract][Full Text] [Related]
29. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
[TBL] [Abstract][Full Text] [Related]
30. Intensity-modulated radiation therapy and xerostomia.
Chambers MS; Weber RS; Garden AS
J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Thorstad WL; Haughey B; Chao KS
Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
[TBL] [Abstract][Full Text] [Related]
33. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
34. Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site.
Bhide S; Clark C; Harrington K; Nutting CM
Med Dosim; 2007; 32(3):188-95. PubMed ID: 17707198
[TBL] [Abstract][Full Text] [Related]
35. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
36. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines.
Guerrero Urbano MT; Clark CH; Kong C; Miles E; Dearnaley DP; Harrington KJ; Nutting CM; PARSPORT Trial Management Group
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):604-13. PubMed ID: 17706404
[TBL] [Abstract][Full Text] [Related]
37. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
[TBL] [Abstract][Full Text] [Related]
38. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
[TBL] [Abstract][Full Text] [Related]
39. Submandibular gland-sparing intensity modulated radiotherapy in the treatment of head and neck cancer: sites of locoregional relapse and survival.
Collan J; Kapanen M; Mäkitie A; Nyman H; Joensuu H; Tenhunen M; Saarilahti K
Acta Oncol; 2012 Jul; 51(6):735-42. PubMed ID: 22150115
[TBL] [Abstract][Full Text] [Related]
40. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
Chao KS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
